EUCTR2011-002114-36-ES进行中（未招募）1 期
Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Subjects was previously enrolled in a denosumab phase 3 study and
- •participated in the Open-label Extension portion of that study.
- •- Subject or subject?s legally acceptable representative has provided
- •informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 198
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 202
排除标准
- •- Subject is of child bearing potential and planning to become pregnant
- •within 7 months after the end of treatment.
- •- Subject is of child bearing potential and is not willing to use, in
- •combination with her partner, two highly effective method of contraception during treatment and for 7 months after the end of treatment.
- •- Subject has known sensitivity to any of the products to be administered during dosing.
- •- Subject will not be available for protocol-required study visits or procedures, to the best of the subject and investigator?s knowledge.
- •- Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
研究者
相似试验
进行中（未招募）
1 期
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerBone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate CancerMedDRA version: 14.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 100000004864EUCTR2011-002114-36-BEAmgen Inc129
进行中（未招募）
不适用
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerBone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate CancerMedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002114-36-LTAmgen Inc168
进行中（未招募）
1 期
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerBone Metastases in Subjects with Advanced Breast Cancer and Bone Metastases in Men with Hormone-Refractory Prostate CancerMedDRA version: 16.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002114-36-HUAmgen Inc129
进行中（未招募）
3 期
Clinical trial to evaluate the efficacy of drug product Denosumab in patients with advance cancer.CTRI/2012/10/003055Amgen Technology Pvt Ltd400
进行中（未招募）
1 期
Open-Label Access Protocol of Denosumab for Subjects with Advanced CancerEUCTR2011-002114-36-PLAmgen Inc129